Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358500 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PDE4BDDB1 | |
| SCHEMBL20360129 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PDE4BDDB1 | |
| SCHEMBL1329486 | 0.87 | RECQL (0.43) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL14697656 | 0.87 | HPGD (0.42) | USP2SMN1; SMN2PDE4BRECQLGPR119 | |
| SCHEMBL17756027 | 0.87 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2PDE4BDDB1 | |
| SCHEMBL15684093 | 0.87 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2PDE4BDDB1 | |
| SCHEMBL408327 | 0.85 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2PDE4BDDB1 | |
| SCHEMBL278133 | 0.83 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2PDE4BDDB1 | |
| SCHEMBL15684240 | 0.81 | NR1H2 (0.40) | NR1H2PDE4BDDB1CRBNTACR1 | |
| SCHEMBL25181675 | 0.81 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2PDE4BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335497-A2 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2024-03-13 | — | — | EP | disclosed |
| EP-3865484-B1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2023-11-08 | — | — | EP | disclosed |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2023-06-15 | — | — | US | disclosed |
| US-11608342-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S (DK) | 2023-03-21 | — | — | US | disclosed |
| CN-114903900-A | PDE9 inhibitors for the treatment of peripheral diseases | 伊马拉公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-3865484-A1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. Lundbeck A/S (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-20210094960-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2021-04-01 | — | — | US | disclosed |
| US-20210085684-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | CARDURION PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3303339-B1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H LUNDBECK AS (DK) | 2021-01-13 | — | — | EP | disclosed |
| CN-112010861-A | PDE9 inhibitors having an imidazotriazinone backbone and an imidazopyrazinone backbone for the treatment of peripheral diseases | H.隆德贝克有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-107810187-B | PDE9 inhibitors having an imidazotriazinone backbone and an imidazopyrazinone backbone for the treatment of peripheral diseases | H.隆德贝克有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-20200062770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2020-02-27 | — | — | US | disclosed |
| US-10513524-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | H. LUNDBECK A/S (DK) | 2019-12-24 | — | — | US | disclosed |
| US-20190307754-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | IMARA, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20180194770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | H. LUNDBECK A/S (DK) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085684-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE12, PDE5A | NR1H2 897/4885USP2 3409/4885SMN1; SMN2 399/4885 |
| US-11608342-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-10513524-B2 | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20190307754-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE12, PDE5A | NR1H2 897/4885USP2 3409/4885SMN1; SMN2 399/4885 |
| US-20180194770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20230183255-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20200062770-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
| US-20210094960-A1 | PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE5A, PDE3A | NR1H2 1711/4885USP2 4239/4885SMN1; SMN2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.